Xcout Intel
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Subscribe to see Vaxcyte, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vaxcyte, Inc. at a glance
Vaxcyte, Inc. is a biotechnology company headquartered in San Carlos, United States. It is publicly listed (PCVX) with a market capitalisation of $10.3B. Xcout tracks 27 named people at Vaxcyte, Inc., including Andrew L. Guggenhime (President & Chief Financial Officer). Xcout recorded 98 job postings from Vaxcyte, Inc. in the last 90 days.
Vaxcyte, Inc. leadership
- Andrew L. GuggenhimePresident & Chief Financial Officer
- Andrew GuggenhimePresident and Chief Financial Officer
- James WassilExecutive Vice President & Chief Operating Officer
- Harp DhaliwalChief Technical Operations Officer
- Chris GriffithChief Business and Strategy Officer
- David McAvoyChief Legal Officer, Chief Compliance Officer & Corporate Secretary
21 more named people on record for Vaxcyte, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Vaxcyte, Inc.
Xcout recorded 98 job postings from Vaxcyte, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Vaxcyte, Inc.'s hiring signals →
Hiring vs the trend
Based on 67 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Vaxcyte, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Vaxcyte, Inc. competitors
A few of Vaxcyte, Inc.'s closest competitors — see the full list of competitors and alternatives →
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Vaxdyn is a Seville-based biotechnology spin-off founded in 2011 that develops safe and effective multi-pathogen vaccines to prevent dangerous bacterial infections.
Vaxxas is a clinical-stage biotechnology company headquartered in Brisbane, Australia. It is commercializing a novel vaccination technology designed to enhance the performance of existing and next-generation vaccines, and opened a biomedical manufacturing facility in Brisbane in June 2023.
Get Vaxcyte, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vaxcyte, Inc. in Xcout Intel
- 27 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access